RA Capital Management 13F holdings, Q2 2015
Holdings as of June 30, 2015 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 58 US equity positions worth $927.6m in its Q2 2015 13F filing. The largest position was AXOVANT SCIENCES LTD at 11.0% of the reported book, followed by ACHILLION PHARMACEUTICALS INC and DYAX CORP. Against the Q1 2015 filing, it opened 14 new positions, added to 6 and reduced 11 among the top 50 holdings.
What did RA Capital Management own in Q2 2015? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2015 |
|---|---|---|---|---|---|---|---|
| 1 | AXOVANT SCIENCES LTD | 11.0% | $101.9m | 5,000,000 | – | new | |
| 2 | ACHILLION PHARMACEUTICALS INC | 9.5% | $88.1m | 9,945,997 | 21% | added | |
| 3 | DYAX CORP | 7.7% | $71.6m | 2,703,093 | -36% | reduced | |
| 4 | TGTX TG THERAPEUTICS INC | Healthcare | 5.9% | $54.8m | 3,302,213 | 6% | added |
| 5 | REGULUS THERAPEUTICS INC | 4.5% | $41.5m | 3,790,476 | 6% | added | |
| 6 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 4.3% | $39.9m | 1,380,320 | -11% | reduced |
| 7 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 4.2% | $38.9m | 2,605,361 | -62% | reduced |
| 8 | DICERNA PHARMACEUTICALS INC | 3.7% | $33.9m | 2,428,571 | 0% | held | |
| 9 | ASND ASCENDIS PHARMA A S | Healthcare | 3.6% | $33.8m | 1,913,153 | 87% | added |
| 10 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 3.0% | $27.6m | 1,545,410 | – | new |
| 11 | ARDX ARDELYX INC | Healthcare | 3.0% | $27.5m | 1,719,945 | – | new |
| 12 | PROTEON THERAPEUTICS INC | 2.9% | $26.9m | 1,506,872 | 21% | added | |
| 13 | XNCR XENCOR INC | Healthcare | 2.5% | $23.6m | 1,075,410 | -50% | reduced |
| 14 | 2655787D BLUEPRINT MEDICINES CORP | 2.5% | $23.3m | 878,348 | – | new | |
| 15 | BELLICUM PHARMACEUTICALS INC | 2.4% | $21.8m | 1,026,402 | 0% | held | |
| 16 | MEDICINES CO | 2.2% | $20.2m | 705,925 | – | new | |
| 17 | BLUEBIRD BIO INC | 2.0% | $18.4m | 109,383 | -45% | reduced | |
| 18 | DVAX DYNAVAX TECHNOLOGIES CORP | 1.9% | $17.9m | 766,000 | -71% | reduced | |
| 19 | CIDARA THERAPEUTICS INC | 1.7% | $16.0m | 1,141,333 | – | new | |
| 20 | NVAX NOVAVAX INC | Healthcare | 1.7% | $15.9m | 1,431,232 | 0% | held |
| 21 | JUNO THERAPEUTICS INC | 1.6% | $14.9m | 280,000 | 0% | held | |
| 22 | AGEN AGENUS INC | Healthcare | 1.5% | $13.8m | 1,600,000 | – | new |
| 23 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 1.5% | $13.5m | 1,220,209 | 0% | held |
| 24 | OMER OMEROS CORP | 1.5% | $13.5m | 749,000 | 0% | held | |
| 25 | TXMD THERAPEUTICSMD INC | 1.4% | $13.2m | 1,680,395 | 0% | held | |
| 26 | AGILE THERAPEUTICS INC | 1.4% | $12.5m | 1,458,792 | 0% | held | |
| 27 | NIVALIS THERAPEUTICS INC | 1.2% | $11.5m | 757,263 | – | new | |
| 28 | MCRB SERES THERAPEUTICS INC | Healthcare | 1.1% | $10.2m | 246,645 | – | new |
| 29 | ALCOBRA LTD | 1.1% | $10.0m | 1,525,894 | – | new | |
| 30 | CONCERT PHARMACEUTICALS INC | 1.1% | $10.0m | 668,406 | 1% | added | |
| 31 | TENX TENAX THERAPEUTICS INC | 1.1% | $9.9m | 2,670,300 | 0% | held | |
| 32 | SUCAMPO PHARMACEUTICALS INC | 0.8% | $7.4m | 450,000 | 0% | held | |
| 33 | ARCA BIOPHARMA INC | 0.7% | $6.5m | 5,678,592 | – | new | |
| 34 | AURIS MED HLDG AG | 0.5% | $4.6m | 940,000 | 0% | held | |
| 35 | AUPH AURINIA PHARMACEUTICALS INC | Healthcare | 0.4% | $3.5m | 1,142,676 | -24% | reduced |
| 36 | TREVENA INC | 0.4% | $3.3m | 528,118 | -60% | reduced | |
| 37 | T2 BIOSYSTEMS INC | 0.2% | $2.2m | 138,002 | 0% | held | |
| 38 | VICAL INC | 0.2% | $1.8m | 2,606,978 | -63% | reduced | |
| 39 | BIOTA PHARMACEUTIALS INC | 0.2% | $1.7m | 807,855 | -42% | reduced | |
| 40 | MERRIMACK PHARMACEUTICALS IN | 0.2% | $1.4m | 116,400 | 0% | held | |
| 41 | T8S TESARO INC | 0.1% | $1.4m | 23,500 | 0% | held | |
| 42 | NEWLINK GENETICS CORP | 0.1% | $1.3m | 30,000 | 0% | held | |
| 43 | REGN REGENERON PHARMACEUTICALS | Healthcare | 0.1% | $1.2m | 2,450 | 0% | held |
| 44 | PTCT PTC THERAPEUTICS INC | Healthcare | 0.1% | $1.2m | 25,800 | 0% | held |
| 45 | ALKS ALKERMES PLC | Healthcare | 0.1% | $1.2m | 19,200 | 0% | held |
| 46 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 0.1% | $1.2m | 24,400 | – | new |
| 47 | CLOVIS ONCOLOGY INC | 0.1% | $1.2m | 13,200 | – | new | |
| 48 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 0.1% | $1.1m | 27,300 | 0% | held |
| 49 | INCY INCYTE CORP | Healthcare | 0.1% | $1.1m | 10,700 | – | new |
| 50 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 0.1% | $1.1m | 9,900 | -44% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.